Search research articles
Contact Us
Filters
Showing results (71-80 of 73) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 73 results.
Journal for Immunotherapy of Cancer
|
March 14, 2024
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 1, 2022
Traffic-related Air Pollution and Lung Cancer Incidence: The California Multiethnic Cohort Study
Iona Cheng, Juan Yang, Chiuchen Tseng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 73) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 73 results.
Journal for Immunotherapy of Cancer
|
March 14, 2024
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 1, 2022
Traffic-related Air Pollution and Lung Cancer Incidence: The California Multiethnic Cohort Study
Iona Cheng, Juan Yang, Chiuchen Tseng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Page
of 8